SuperworthEntrada Therapeutics EPS TRDA
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$3.96
- Latest quarter, Q2 FY26
- −$1.01
- Fiscal year 2025
- −$3.46
- −281% on the year before
Entrada Therapeutics' earnings per share was −$3.96 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.01.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.46 | −281% |
| FY2024 | $1.91 | n/a |
| FY2023 | −$0.26 | n/a |
| FY2022 | −$3.02 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.01 | n/a | −$3.96 | |
| Q1 FY26 | −$0.95 | n/a | −$3.99 | |
| Q4 FY25 | −$0.94 | −3233% | −$3.46 | |
| Q3 FY25 | −$1.06 | n/a | −$2.49 | |
| Q2 FY25 | −$1.04 | −167% | −$1.78 | |
| Q1 FY25 | −$0.42 | −162% | $0.81 | |
| Q4 FY24 | $0.03 | n/a | $1.91 | |
| Q3 FY24 | −$0.35 | −134% | $1.59 | |
| Q2 FY24 | $1.55 | n/a | $2.96 | |
| Q1 FY24 | $0.68 | n/a | $0.63 | |
| Q4 FY23 | −$0.29 | n/a | −$0.26 | |
| Q3 FY23 | $1.02 | n/a | −$0.76 |
Against its peers
Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TRDAEntrada Therapeutics | −$3.96 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Entrada Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.